The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid to focus resources on a pair of cancer cell therapies.

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

Cancer completely disappeared from two-thirds of 24 patients treated with a combination of the antibody petosemtamab and ...

Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

What if business leaders approached strategy the way scientists design gene delivery vectors? In biotechnology, precision, ...

Scientists have launched a miniature lab into Earth's orbit, which contains microbes designed to produce proteins in space.

In the heart of Austin, where music and innovation often intersect, beloved local Casey McPherson’s story has struck a chord ...

When the board of Belgian biotech Galapagos asked Paul Stoffels to become CEO, he told them he was only interested in doing ...

Merck KGaA in talks to acquire SpringWorks Therapeutics for $47/share ($3.5B), gaining cancer drugs Ogsiveo and Gomekli. Deal ...

Developments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals ...

Kendall Square has become a hub of biotech innovation and a popular location for up and coming life sciences firms. Now, a ...